
Nadia Hameed, MD
@nadiausamc
Physician, GYN Pathologist, Assistant Professor, UT-MD Anderson Cancer Center
ID: 905791426205814788
07-09-2017 13:54:39
382 Tweet
1,1K Followers
650 Following

Excited to visit Mayo Clinic to discuss endometrial cancer research! Great partnership with MD Anderson Cancer Center Memorial Sloan Kettering Cancer Center #endcancer #oncsurgery Karen Lu Jolyn Taylor Lauren Cobb, MD Mikayla Borthwick Bowen







The lack of progress in Ovarian Ca. The morphology of Ts is the result of different genes. How r we going to find different genes if we call all these types Serous Ca? The tumors are saying: โwe are differentโ ๅ็ ๅๅค


Early lesions r needed to find out how anything starts. Incidental HGOvCa. Only 5 microscopic lesions found. 3. In Ov, 1 in FT serosa, 1 in Ut serosa. They prove: 1-Multicentricity 2-Origin in flat epithelium in Ov, and in the stroma (Fere ex nihilo) in FT serosa.ๅ็ ๅๅค


Using nice diagrams,researchers have shown us the two very different molecular pathways of serous Ts. Real, every day life, can b different. Serous LMP associated with HGSCa. In pathology we can do research every day, without a lab or a grant, and generating $.ๅ็ ๅๅค


Houston, we solved the problem(of ovarian serous Ts) Human Path 127,136-145,2022. Precursors in the ovarian stroma. Younger Pts-endosalpingiosis--> serous borderline-->LGSCa. Older Pts-simple cysts-->HGSCa These changes correlate with the development of the Mullerian system ๅ็ ๅๅค

Deep gaps in pathology training. Not enough emphasis on H&E. Obvious endometrioid carcinoma in ovary diagnosed as low grade serous carcinoma because of a wild type p53. ๅ็ ๅๅค


I am pleased to share our recently identified GYN marker. SOX17 is more specific than Pax8. It doesnโt express in kidney, thyroid, breast, lung, GI and many other organ tumors. It has been validated in clinical diagnosis at MD Anderson Cancer Center recently.authors.Elsevier.com/a/1gOgG3B8d8sVโฆ





Bassem Youssef ูููุช ููููุช.

